TGFB1 and neoplasm: Our findings suggest that targeting SDF-1 and TGFβ in BM using a triple-combination with BTZ, LEN, and Thal, potentially improve the response of myeloma cells by increasing the inhibition of myeloma cell growth and activating the endogenous immune surveillance against tumor antigens.